title: Fasting serum concentration of apolipoprotein B48 represents residual risks in patients with new-onset and chronic coronary artery disease.
abstract: BACKGROUND
  To identify new therapeutic targets for coronary artery disease (CAD), we investigated whether fasting serum concentration of apolipoprotein (apo) B48 could be a marker for CAD.
  
  
  METHODS
  Patients with CAD were divided into those with new-onset CAD [i.e., those receiving percutaneous coronary intervention (PCI) for the first time] and those with chronic CAD (i.e., those receiving follow-up coronary angiography). Fasting serum biochemical analyses were performed on admission and 6 months after the PCI.
  
  
  RESULTS
  On admission, serum LDL-C concentrations in patients with chronic CAD (n=138), presumably receiving statin treatment, were lower than in patients with new-onset CAD (n=50, p<0.02) or without CAD (n=71, p<0.001). Nevertheless, apoB48 was higher in CAD patients than in those without CAD (p<0.001). After adjusting for classic cardiovascular risk factors, multivariate logistic regression analyses showed apoB48 to be an independent predictor of coronary risk in new-onset or chronic CAD, irrespective of the LDL-C levels. Moreover, apoB48 was markedly increased during the follow-up period in CAD patients having new lesion progression after the prior PCI.
  
  
  CONCLUSIONS
  Fasting serum apoB48 concentration could be a marker of new onset as well as chronic CAD, and predict new lesion progression in secondary prevention.
authors: Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Chuo-ku, Kobe 650-0017, Japan. kent.mory@gmail.com
authors: Kenta
authors: K
authors: Mori
authors: Tatsuro
authors: T
authors: Ishida
authors: Tomoyuki
authors: T
authors: Yasuda
authors: Tomoko
authors: T
authors: Monguchi
authors: Maki
authors: M
authors: Sasaki
authors: Kensuke
authors: K
authors: Kondo
authors: Minoru
authors: M
authors: Hasokawa
authors: Hideto
authors: H
authors: Nakajima
authors: Yoko
authors: Y
authors: Haraguchi
authors: Li
authors: L
authors: Sun
authors: Masakazu
authors: M
authors: Shinohara
authors: Ryuji
authors: R
authors: Toh
authors: Kunihiro
authors: K
authors: Nishimura
authors: Ken-ichi
authors: K
authors: Hirata
mesh_terms: D000368:Aged; D053283:Apolipoprotein B-48 / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D002908:Chronic Disease; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000097:blood* / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000188:drug therapy; D005215:Fasting; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D062645:Percutaneous Coronary Intervention; D012307:Risk Factors
chemical_list: D053283:Apolipoprotein B-48; D015415:Biomarkers; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors